Based on our preclinical findings, we are assessing the efficacy of intratumoral injection of dendritic cells (DC) transduced with an adenoviral vector expressing the secondary lymphoid chemokine (CCL21) gene (Ad-CCL21-DC) in a phase I trial in advanced non-small cell lung cancer (NSCLC). While this approach shows immune enhancement, the preparation of autologous DC for CCL21 genetic modification is cumbersome, expensive and time consuming. We are evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery to mediate antitumor activity in lung cancer.
Here we describe that vault nanocapsule platform for CCL21 delivery elicits antitumor activity with inhibition of lung cancer growth. Vault nanocapsule packaged CCL21 (CCL21-vaults) demonstrated functional activity in chemotactic and antigen presenting activity assays. Recombinant vaults impacted chemotactic migration of T cells and this effect was predominantly CCL21 dependent as CCL21 neutralization abrogated the CCL21 mediated enhancement in chemotaxis. Intratumoral administration of CCL21-vaults in mice bearing lung cancer enhanced leukocytic infiltrates (CXCR3+T, CCR7+T, IFNγ+T lymphocytes, DEC205+ DC), inhibited lung cancer tumor growth and reduced the frequencies of immune suppressive cells [myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), IL-10 T cells]. CCL21-vaults induced systemic antitumor responses by augmenting splenic T cell lytic activity against parental tumor cells.
Citation: Kar UK, Srivastava MK, Andersson Å, Baratelli F, Huang M, Kickhoefer VA, et al. (2011) Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth. PLoS ONE 6(5): e18758. https://doi.org/10.1371/journal.pone.0018758
Editor: Siyaram Pandey, University of Windsor, Canada
Received: December 21, 2010; Accepted: March 9, 2011; Published: May 3, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by a University of California Discovery Grant (to LHR and VAK) a Jonnson Comprehensive Cancer Center Fellowship to UKK) and by National Institutes of Health Grants (RO1 CA95686 and RO1 CA126944), University of California Los Angeles Lung Cancer Program, Department of Veterans Affairs Medical Research Funds and Tobacco Related Disease Program Award Program of University of California (15RT-0207). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Lung cancer is the leading cause of cancer death in the United States and worldwide . To date with the existing forms of therapy, the overall long term survival is only 15%. Thus, new therapeutic strategies are needed. We are evaluating a novel vault nanocapsule as a proof of concept for the delivery of immune potentiating cytokines for an “off the shelf reagent” for immune based therapy for lung cancer.
Vaults are cytoplasmic ubiquitous ribonucleoprotein particles first described in 1986 . Native vaults are 12.9±1 MDa ovoid spheres with overall dimensions of approximately 40 nm in width and 70 nm in length , , present in nearly all-eukaryotic organisms with between 104 and 107 particles per cell . Despite their cellular abundance, vault function remains elusive although they have been linked to many cellular processes including the innate immune response, multidrug resistance in cancer cells, multifaceted signaling pathways, and intracellular transport .
As a naturally occurring nanocapsule, the vault particle may be an ideal structure to engineer as a therapeutic system for compound encapsulation, protection, and delivery. Vaults are highly stable structures in vitro, and a number of studies indicate that the particles are non-immunogenic . Vaults can be engineered and expressed using a baculovirus expression system and heterologous proteins can be encapsulated inside of these recombinant particles using a protein-targeting domain termed INT for vault INTeraction. Several heterologous proteins have been fused to the INT domain (e.g. fluorescent and enzymatic proteins) and these fusion proteins when packaged into the recombinant vaults, retain their native characteristics, and thus confer new vault properties , .
CCL21 has been identified as a lymphoid chemokine that is predominantly and constitutively expressed by high endothelial venules in lymph nodes and Peyer's patches, lymphatic vessels and stromal cells in spleen and appendix . CCL21 binds to the chemokine receptor CCR7 and is a chemoattractant for mature dendritic cells (DC), naive and memory T cells , . This chemokine, along with CCL19, is required for normal lymphoid tissue organization that is ultimately essential for effective T cell-DC interactions. Natural killer (NK) and natural killer T (NKT) antitumor effectors also express CCR7 receptor and are chemo attracted by CCL21. The use of chemokines to attract DC, lymphocyte, NK and NKT effectors into tumors can serve as an effective antitumor strategy. Based on this concept, we have previously shown that intratumoral administration of recombinant CCL21 reduces tumor burden in murine lung cancer models . The antitumor activity induced by recombinant CCL21 however required high and frequent dosing because proteins administered intratumorally are not retained locally for prolonged periods. Although these studies delineated the role of CCL21 as an effective antitumor agent, frequent high dose intratumoral administration is clinically limiting with the potential of unnecessary systemic toxicity. Based on the limitations of this approach, we examined the use of DC for intratumoral CCL21 delivery , . In preclinical studies we demonstrated that intratumoral administration of CCL21 gene modified DC led to tumor eradication in murine lung cancer models. Following our initial description of the antitumor activities of CCL21, several groups have reported that CCL21 has potent antitumor properties in a variety of model systems , , , , . In all models, CCL21 demonstrated potent regression of tumors, which was shown to be dependent on host T cell immunity.
Based on extensive pre-clinical evaluation, we began an NCI funded clinical trial one year ago assessing the intratumoral injection of DC transduced with an adenoviral vector expressing the CCL21 gene (Ad-CCL21-DC) in a phase I trial in advanced non-small cell lung cancer (NSCLC) . While our clinical studies utilizing intratumoral administration of CCL21 gene modified DC shows immune enhancement, the preparation of CCL21 expressing autologous DC is cumbersome, expensive and time consuming. An efficacious off-the-shelf reagent would facilitate the evaluation of this chemokine-based therapy. Towards achieving this goal, we are evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery for the purpose of initiating antitumor immune responses in lung cancer. We anticipate that the use of vault nanoparticles will circumvent autologous DC preparation, minimize batch to batch variability and allow for comparability and standardization. In addition, vault nanoparticles engineered to release CCL21 can be used to treat a broad range of malignancies.
In this study we evaluated the effect of vault nanocapsule delivery of CCL21 on the growth of Lewis Lung (3LL) tumors in vivo. Our findings indicate that a single intratumoral administration of CCL21-vault nanocapsules recruits antitumor effectors, induces potent antitumor activity and inhibits tumor growth.
Materials and Methods
The CCL21 cDNA was fused in frame to either INT or mCherry-INT . Murine CCL21 was PCR amplified with the primers: CCL21- forward GCGCGGATCCCCATGGCTCAGATGATG and CCL21- reverse GCGCAGATCTTCCTCTTGAGGGCTGTGTCTG. To form mCCL21-mCherry-INT in pFastBac, purified CCL21 PCR product was digested with BamH1 and Bgl I and ligated to BamH1 phosphatase treated mCherry-INT pFastBac. Human CCL21 was PCR amplified with the primers: CCL-21 F-SpeI CCCCACTAGTC CAGTTCTCAGTCACTGGCTCTG, CCL-21-NheI CCCCGCTAGCTGGCCCTTTAGGGGTCTGTG, INT with NheI CCCCGCTAGCTGCACACAACACTGGCAGGA, INT with XhoI GGGGCTCGAGTTAGCCTTGACTGTAATGGA to form hCCL21-INT. Recombinant (r) baculoviruses were generated as described . Sf9 cells were infected with mCCL21-mCherry-INT, hCCL21-INT or CP-MVP encoding baculoviruses at a multiplicity of infection (MOI) of 0.01 for 65 h. The infected cells were prepared as described . Lysates containing CP-MVP vault were mixed with lysates containing mCCL21-mCherry-INT or hCCL21-INT and were incubated on ice for 30 min to allow the INT fusion proteins to package inside of vaults. Vault were purified as described , resuspended in sterile PBS and protein concentration determined by BCA assay (Bio-Rad, CA). Sample integrity was analyzed by negative stain electron microscopy or Coomassie staining of SDS-PAGE followed by Western blot analysis. CCL21-INT protein in the vault was quantified by densitometric analysis of Western blots against purified recombinant INT protein as standard.
Primary antibodies for western blot analyses were rabbit anti-MVP antibody (1/1000 dilution)  or rabbit anti-VPARP antibody (1/500 dilution)  and secondary goat anti-rabbit HRP-antibody (1∶2000 dilution) (Amersham). The CCL21 and CXCR3 (220803) mAb were from R&D, (Minneapolis, MN), primary immunostaining CD3 mAb was from DAKO (Cytomation, Carpinteria, CA, USA). FlTC, PE, APC, PerCP or PerCP-Cy7-conjugated anti-mouse mAbs to CD3 (145-2C11), CD4 (RM4-5), CD8α (53-6.7) and isotype control antibody were from BD Biosciences (San Diego, CA), mAbs to detect Tregs with CD4 (GK1.5), CD25 (PC61), intranuclear Foxp3 (FJK-16s) IL-10 (JES5-16E3), IFNγ (XMG1.2), DEC205 (205yekta), CCR7 (4B12) and EpCam (G8.8) were from eBioScience(San Diego, CA), mAb CD11b (M1/70), Gr1 (RB6-8C5), were from BioLegend (San Diego). Bradford protein quantification dye was from Sigma.
Chemotaxis assays were performed using 24-well plates with 3 µm pore size inserts (Costar/Corning, Corning, New York) according to the manufacturer's instructions. 2.0×105 T2 cells in serum-free medium were loaded in the upper chamber. 200 ng/ml of CCL21-mcherry-INT/vault, 600 ng/ml rCCL21 (R&D), 200 ng/ml CCL21-mCherry-INT/CP-MVP vault with neutralizing CCL21 antibody (5 µg/ml), 600 ng/ml CCL21 with CCL21 antibody (5 µg/ml) were added to the lower chambers. After 2 hr incubation, migrated cells were enumerated by FACS.
Antigen processing and presentation assay
DC2.4 (5×104c/well) were plated in 96-well plates with OVA protein (350 µg/ml), CD8 T cell line B3Z (105c/well), in the presence of control vaults (200 ng/ml), or mCCL21-vaults (200 ng/ml) or rCCL21 (200 ng/ml) for 24 hrs. To determine the impact of CCL21 on APC activity, CCL21 was neutralized with anti-CCL21 Ab (5 µg/ml). IL-2 secreted by activated CD8 T cells was quantified by ELISA (eBioScience).
The Lewis lung carcinoma cell line (3LL) was obtained from ATCC (Manassas, VA) and was cultured as described . The cell line was mycoplasma free and utilized before the tenth passage.
Pathogen-free C57BL/6 mice or UBC-GFP/BL6 (6–8 wk old; Jackson Laboratory) were maintained in the Veterans Affairs Animal Research vivarium in accord with the institution's animal review board guidelines. All animal work was conducted in accord with the Veterans Affairs Institutional Animal care and Use Committee guidelines: id A3002-01. The institutional review board approved all the studies involving animals in this manuscript. Animals exhibiting signs of pain or meeting the endpoint criteria were euthanized immediately according to the accepted institution based protocol. 3LL tumor cells (1.5×105) were injected s.c. in the right suprascapular area of mice. Mice bearing 9-day-old established tumors were treated with a single intratumoral injection of mCCL21-mCherry-INT/CP-MVP vaults (200 ng), CP- MVP vaults (200 ng) in 200 µl or NS diluents. Tumor volumes were monitored and calculated as described . To determine the lymphocytes infiltrating the tumors, UBC-GFP/BL6 mice bearing 9-day tumors were treated and 7 days post treatment, non-necrotic tumors were isolated and frozen in OCT. The frozen tissue was sectioned, fixed and counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and observed under a 1×71 Olympus fluorescence microscope. The images were acquired using the Image Pro software.
3LL-GFP cells (5×103) were implanted in the left lung as described . One week following tumor inoculation, mice were treated with diluent, control vaults or mCCL21-vaults via transthoracic injection. Four weeks after tumor implantation, lungs were harvested for evaluation of tumor burden and leukocytic infiltrates as described .
Tumors section were prepared according to standard protocol . Slides were incubated with primary antibody (CD3 1∶200) overnight at 4°C, washed and incubated with secondary biotinylated. The slides were developed with Vectastain ABC-AP kit and Vector Red substrate solution (Vector Laboratories, Burlingame, California). Slides were counterstained with hematoxylin.
FACs analyses was performed for CD3, CD4, CD8, CCR7, CD11b, Gr1, DEC205, CD25, FOXP3, CXCR3 and intracytoplasmic T cell IFNγ and IL-10 on a single lung tumor cell suspension as described .
T cell Cytolysis
Splenic T lymphocyte lysis was evaluated against autologous 3LL and control B16 melanoma cells as described .
Packaging CCL21 into recombinant vaults
Several exogenous proteins have been packaged inside of recombinant vaults (luciferase, green fluorescent protein, mCherry fluorescent protein, adenovirus protein VI, and the major outer membrane protein of Chlamydia) when fused to a 162 amino acids vault-targeting domain (INT) derived from the vault-associated protein (VPARP, amino acids 1563–1724). These fusion proteins bind with high affinity to the interior of the vault particle, are protected from the external environment, and retain their native properties, thus conferring new characteristics onto the recombinant vault particles , , . The mouse chemokine CCL21 was fused to INT to create a CCL21 fusion protein (mCCL21-INT) that can be packaged inside of recombinant vaults. Mixing of lysates containing recombinant CCL21-INT and rat MVP generated in Sf-9 cells allowed the formation of a macromolecular vault complex containing the CCL21 fusion protein that could be isolated by density gradient ultracentrifugation. The purified vaults contained both MVP as well as CCL21-INT (henceforth referred to as CCL21-vaults) as indicated by Coomassie staining and immunoblot analyses (Fig. 1). For these studies three different vaults were prepared. One was packaged with mouse CCL21 fused to the fluorescent protein mCherry-INT (mCCL21-mCherry-INT/CP-MVP vaults, abbreviated here mCCL21-vaults), a second vault was packaged with human CCL21-INT (hCCL21-INT/CP-MVP vaults, abbreviated here hCCL21-vaults) and the third was a control empty vault (CP-MVP vaults ) (Fig. 1A and B). We estimated the amount of CCL21 packaged inside the vaults by quantitative Western blots. Our analysis indicated that 20–30 molecules of the CCL21-INT protein were packaged in each CCL21-vault particle. This is consistent with our previous experience in packaging multiple copies of other INT fusion proteins into recombinant vaults . With an estimate of 20–30 CCL21-INT proteins per vault, it is likely that this is at or near a saturating level for the packaging of this size protein. The CCL21-vaults also exhibited a very similar sedimentation profile on sucrose gradients as vault particles containing the INT domain fused to luciferase, , ,  suggesting that incorporation of CCL21-INT did not impact the normal structure of recombinant vault particles. To verify this, we examined purified vault complexes by negative stain transmission electron microscopy (Fig. 1C). The CCL21-vaults exhibited the characteristic barrel shaped morphology of vaults, consistent with the previously established morphology of vaults containing recombinant-INT fusion proteins , .
A. Coomassie stain of purified vaults fractionated on a 4–16% SDS-PAGE. Lane 1, molecular weight markers. Lane 2, mCCL21-mCherry-INT/CP-MVP vaults. The 97-kDa MVP band is indicated by the arrow. Lane 3, hCCL21-INT/CP-MVP vaults. Lane 4, CP-MVP vaults. B. Western blot analyses of purified vaults to confirm the presences of MVP or the indicated INT fusion proteins (arrows). Lane 1, mCCL21-mCherry-INT/CP-MVP vaults were immunoblotted with anti-MVP antibody. Lane 2, mCCL21-mCherry-INT/CP-MVP vaults were immunoblotted with anti-INT antibody. Lane 3, hCCL21-INT/CP-MVP vaults were immunoblotted with anti-INT antibody. C. Negative-stained electron micrographs of purified vaults. CP-MVP vaults (left), mCCL21-mCherry-INT/CP-MVP vaults (center), hCCL21-INT/CP-MVP vaults (right).
CCL21-vaults are biologically active and induce the migration of T2 cells and enhance DC APC activity
A chemotaxis assay was used to determine if CCL21 retains biological function when packaged in the recombinant vaults. The chemotactic activity of CCL21 is mediated through its receptor CCR7 to induce the migration of T cells and DC. To evaluate the biological activity of CCL21 in the vault, we used T2 hybridoma cells that constitutively express CCR7. Two different concentrations of CCL21-vaults (200 ng and 600 ng), empty vaults (600 ng), and recombinant CCL21 (600 ng) were placed in the bottom chamber of a 24-well transwell plates and 2×105 T2 cells were added to the upper chamber. The number of cells that migrated to the lower chamber was determined by flow cytometry and represented as % migration (Fig. 2A). More than 7.5% of the T2 cells responded to 200 ng of mCCL21-vaults compared with ≤2.5% of the T2 cells incubated with 600 ng of recombinant CCL21. This is a potent response considering that the concentration noted above is for CCL21-vaults and the actual concentration of CCL21 in the vaults is estimated to be ≤20 ng. The increased bioactivity of mCCL21-vaults may be due to increased stabilization of CCL21 resulting from packaging of the protein into the protective environment of the vault lumen. As the fusion protein non-covalently associates within vaults, the vault breathing in solution may release CCL21 in a gradient fashion. Thus the number of cells migrating in response to mCCL21-vaults was higher than the recombinant CCL21 because a steeper gradient is formed. To determine if the migration of T2 cells was CCL21-dependent, an anti-CCL21 neutralizing antibody was utilized to block the chemotactic activity of both recombinant CCL21 and mCCL21-vaults. The anti-CCL21 blocked mCCL21-vault functional activity indicating chemotactic activity in a CCL21 specific manner (Fig. 2A). The impact of mCCL21-vaults on DC APC activity was evaluated in vitro. In comparison to control vaults, mCCL21-vaults augmented DC capacity to process and present ovalbumin and activate CD8 T cells to secrete IL-2. Neutralization of CCL21 abrogated the increase in DC APC activity to control levels (Fig. 2B). Similar results were observed with hCCL21-vaults on DC APC activity (data not shown).
A. CCL21-vaults increased the migration of T2 cells. 2.0×105 T2 cells were plated in serum-free medium in the upper chamber. mCCL21-mCherry-INT/CP-MVP vaults (200 ng/ml or 600 ng/ml), recombinant CCL21 (600 ng/ml), control vaults (CP-MVP vaults 600 ng/ml) or neutralizing anti-CCL21 recombinant antibody (5 µg/ml) were added to the lower chamber of the wells. Following 2 hr incubation, migration of T2 cells were analyzed by flow cytometry. mCCL21-vaults effectively increased the T2 migration as compared with control. Anti-CCL21 neutralizing Ab to CCL21 abrogated the increase in T2 migration suggesting that CCL21 in the vault predominantly mediate the chemotatic migration of T2 cells. Data in the panel are representative of 2 independent experiments. Bars; Mean ± SEM, *p<0.05 between the mCCL21-vaults and control vaults or anti-CCL21 antibody treatment groups. B. mCCL21-vaults enhanced DC APC activity and blocking CCL21 reversed the increase in APC activity. B3Z cells (1×105 cells/200 µl/well) were co-cultured with DC 2.4 (5×104 cells/200 µl/well) and ovalbumin (350 µg/ml) in the presence or absence of mCCL21-vaults (200 ng/ml) and anti-CCL21 antibody (5 µg/ml) or control antibody (5 µg/ml goat IgG) for 24 hrs. Control vaults were used at a concentration of 200 ng/ml. T cell activation status was measured by IL-2 production by ELISA. Data are representative of 2 independent experiments. Bars; Mean ± SEM, *p<0.05 between the mCCL21-vaults and control vaults or anti-CCL21 antibody treatment groups.
CCL21-vaults enhance the recruitment of leukocytic infiltrates and inhibit 3LL tumor growth
We determined the antitumor activity of mCCL21-vaults on established 3LL tumor in vivo. A single intratumoral injection of mCCL21-vaults (200 ng) led to significant decrease in tumor growth compared to empty vaults (Fig. 3A). The mCCL21-vault treatment group showed enhanced intratumoral leukocytic infiltrates compared to control vaults (Fig. 3B) and immune staining demonstrated that the infiltrates were predominantly CD3 expressing T cells (Fig. 3C bottom right panel). The antitumor efficacy of mCCL21-vaults was determined in the 7-day established orthotopic 3LL lung cancer model. mCCL21-vaults inhibited tumor burden by 7-fold compared to controls (Fig. 4A–B). In the control treatment groups (diluents or control vault), there were 7–9% decrease in the average body weight at the end of the experimental duration but no significant weight change was observed in the CCL21-vault treatment group. An evaluation of intratumoral leukocytic populations showed enhanced frequency of CD4, CD8, CD3 CXCR3, CD3 CCR7 and DEC205 but reduced frequency of MDSC and Tregs (Fig. 4C).
A. CCL21-vaults inhibited tumor growth and enhanced intratumoral T cell infiltrates in lung cancer. C57BL/6 mice bearing 9 day 3LL established tumors (s.c.) were treated intratumorally with control vaults (200 ng), mCCL21-vaults (200 ng) or diluent normal saline (NS). Bisecting tumor diameters were measured with calipers. B–C. mCCL21-vaults increased the influx of CD3 expressing T cells in the tumor as compared to control vaults. UBC-GFP/BL6 mice bearing 9-day established tumors were treated intratumorally with control vaults or mCCL21-vaults. OCT frozen tissue was sectioned, fixated onto slides, and counterstained with the nuclear dye DAPI (blue). Control tumors (top panel) demonstrate very limited green fluorescence (infiltrating cells) under a high-power view (magnification, ×400). Most green fluorescent cells are large polygonal stromal cells while tumor cells are counterstained blue by DAPI. Immune staining for T cells shows very few CD3 expressing T lymphocytes (top right panel). In contrast, prominent tumor-infiltrating lymphocytes, small round green fluorescent cells are evident in tumors from the mCCL21-vault-treated mice (arrow, bottom panel). Immune staining for T cells shows that the infiltrates are CD3 expressing T cells (bottom right). Data; Mean ± SEM, *p<0.05 between mCCL21-vault and control group, n = 10 mice/group.
5×103 3LL-GFP tumor cells were injected in the left lung via transthoracic route. One week after tumor injections, mice were treated with diluent (NS), control vaults (2 µg) or mCCL21-vaults (2 µg) via transthoracic route in the left lung. Day 28 post tumor implantation, lungs were harvested for the analysis of tumor burden and leukocytic infiltrates. A. H&E staining of lung tumor sections from diluent or control vaults showed increased tumor masses (tumor mass depicted by arrow top panel and infiltrates bottom right panel) as compared to reduced tumor mass in the CCL21-vault treatment group. B. Tumor burden was calculated on total percentage of GFP and Epcam expressing tumor cells in total lung digest. Naïve lung was used as control to set up the gate. CCL21-vault treatment reduced tumor growth. C. CCL21-vaults augmented CD4, CD8, CXCR3+CD3+T, CCR7+CD3+T and DEC205+DC infiltrates and had reduced frequencies of MDSC and Tregs. D–E. The CCL21-vault treated mice had increased tumor infiltrates with high IFNγ but reduced IL-10 expressing T cells compared to controls. F. CCL21-vault treatment enhanced the cytolytic activity of purified splenic T cells against parental 3LL tumors in vitro (E∶T of 20∶1 and 40∶1). Data bars, mean ± SEM, *p<0.05 between CCL21-vaults and control vault groups, n = 10 mice/group.
CCL21-vaults increase tumor infiltrating T cells with enhanced IFNγ but reduced IL-10 and augment systemic T cell cytolytic activity
Tumor T lymphocytic infiltrates from mCCL21-vault treated mice had increased intracytoplasmic IFNγ and reduced IL-10 (Fig. 4D–E). Intratumoral mCCL21-vaults induced systemic antitumor immune activity: splenic T cells from mCCL21-vault treated mice had augmented lytic activity against parental tumor cells in vitro (Fig. 4F).
We have previously shown that intratumoral recombinant CCL21 or CCL21 gene modified DC induce a T cell dependent tumor reduction in murine models of lung cancer , , ,,. Based on extensive preclinical modeling, we have translated our intratumoral DC-AdCCL21 approach to treat advanced stage lung cancer in a phase I clinical trial. Although the initial results of this trial suggest immune enhancement, we are evaluating CCL21 delivery mechanisms that will obviate the need to isolate and culture autologous DC. To this end we evaluated CCL21-vault nanocapsules as an “off the shelf” therapeutic platform against tumor growth in vivo utilizing the well characterized 3LL cancer model. Our rationale for administration of intratumoral CCL21-vault nanocapsules is to promote the recruitment of T lymphocytes and DC into the tumor microenvironment for a robust antitumor activity.
As a naturally-occurring, non-immunogenic, protein-based nanoscale capsule, the vault particle has the potential to serve as a flexible therapeutic delivery vehicle. Engineered in the baculovirus system, the particle self-assembles from a single expressed protein which can be modified to allow cell targeting, specific endocytosis and endosome penetration , , , . Proteins and peptides fused to a vault targeting domain are packaged in the particle, protected from the external environment and released slowly. This is the first study to describe that vault nanocapsules can be engineered to package and retain biologically active CCL21. Our results demonstrate that although empty vaults and rCCL21 are each chemotactic, packaging the chemokine into vault synergistically enhanced T cell migration, suggesting that the sustained release of CCL21 by the vault particle can establish a steep chemotatic gradient. Neutralizing antibodies to CCL21 abrogated the chemotactic activity of the CCL21-vault demonstrating that the chemotactic activity was predominantly CCL21 dependent. Based on the results of chemotactic experiments, we evaluated the impact of CCL21-vaults on DC APC activity. CCL21-vaults augmented DC APC activity and neutralization of CCL21 abrogated this activity. In comparison to rCCL21, CCL21-vaults stimulated DC APC activity to greater levels at one tenth the concentration of rCCL21, suggesting a greater DC affinity for the CCL21-vault nanocapsule.
Based on our in vitro findings, CCL21-vaults were evaluated in a therapeutic lung cancer model in vivo. Our results demonstrate that the vault design is effective at inhibiting the growth of established tumors. A single intratumoral injection of CCL21-vaults led to significant inhibition in tumor growth compared to controls. Our data suggests that the CCL21-vault formulation is as effective in comparison to the frequent high doses of rCCL21 . In both the subcutaneous and orthotopic lung tumor models the CCL21-vault therapy was administered intratumorally. In future studies when evaluating the efficacy of tumor antigen specific vault nanocaspsules vaccination routes in the protective and therapeutic settings that include i.v or i.p. delivery routes, changes in plasma/serum transaminase level will be quantified for vault effects on liver function. Although in the migration assay, the control vaults demonstrated chemotactic activity, control vaults did not affect tumor growth compared to the diluents treatment group. This suggests that CCL21 is the critical component in the vault nanocapsule for the induction of antitumor activity. In future work we will screen both the pro-apoptotic and anti-apoptotic proteins in the tumors to determine changes in response to CCL21-vault nanocapsule therapy to mechanistically explore the apoptotic programs induced by this therapy. In vivo, human CCL21 containing vaults were as effective as the murine CCL21-vault in reducing 3LL tumor growth (data not shown). In comparison to controls, CCL21-vault treatment resulted in extensive tumor T and DC leukocytic infiltrates. Intratumoral infiltration by elevated frequencies of T lymphocytes ,  and APC  in lung cancer is associated with a better patient outcome. There was an increased IFNγ and reduced IL-10 cytokine signature of T lymphocytes infiltrating the tumors of CCL21-vault treated mice. Based on our previous observations with rCCL21 in preclinical models , the increased frequency of T cell subsets (CD4 and CD8), CXCR3 and CCR7 expressing T cell effectors and DC in the lung tumor microenvironment is beneficial and most probably responsible for enhanced antitumor activity of CCL21-vaults. In a recent study, Dieu-Nosjean et al.  retrospectively identified ectopic lymph node or tertiary lymphoid structures within human non-small cell lung cancer specimens and demonstrated a correlation of the cellular content with clinical outcomes. The density of DC-Lamp+, mature DC within these structures was a predictor of long-term survival in the selected lung cancer patient population. The authors observation that a low density of tumor-infiltrating CD4+ and T-bet+T lymphocytes were present in tumors poorly infiltrated by DCLamp+ mature DC provides additional supportive evidence for the prognostic importance of an adaptive immune reaction to a solid tumor . In the present study we do not know if the involvement of CD1d-mediated antigen presentation to NKT cells contributes to the antitumor activity of CCL21-vault nanocapsules. However since NKT cells express the CCR7 receptor, future work will delineate their role in CCL21-vault nanocapsule mediated antitumor reactivity.
Immune suppression has a crucial role in promoting tumor progression. Treg and MDSC contribute to immune suppression in the tumor bearing host. Although T cells accumulate in lung cancer tissues they fail to respond because a high proportion of tumor infiltrating lymphocytes (TIL) are Tregs , . Treg cells actively down regulate the activation and expansion of antitumor reactive T cells , ,  and NK cells . In addition to Tregs, MDSC have a strong suppressive activity in cancer patients , , ,  and tumor-bearing mice , , . These immune suppressive cells inhibit T cell ,  and NK cell activity ,  and pose a significant hurdle to successful immune based therapy. The reduction in these immune suppressor phenotypes may enhance immune based anti tumor approaches. We found that in comparison to controls, CCL21-vault therapy group had reduced the frequencies of Treg and MDSC and systemically enhanced T lymphocytic lysis of parental tumor cells. Thus the benefit of utilizing CCL21-vaults is the recruitment and activation of antitumor effectors and reduced frequencies of Treg and MDSC immune suppressors.
Our combined results indicate that the CCL21-vault nanocapsule platform is an effective antitumor strategy. This holds significance for broad application as an off the shelf reagent for cancer therapy. We have demonstrated that vault nanoparticles containing the major outer membrane protein of Chlamydia, could be delivered to the respiratory tract, by the intranasal route and induced robust anti-chlamydial immune responses . The addition of EGF onto the outside of vault particles can be used to specifically target cells expressing high levels of EGFR and leads to phosphorylation of Tyr1173 on the receptor . This suggests that vault particles can be designed as multifunctional vehicles that can be further engineered for target specific delivery as well as carriers of specific payloads that can act as tumor antigens to prime the immune system to potentially act as vaccines to prevent tumor recurrence and metastasis. These multifunctional nanoparticles may prove indispensable as cancer therapeutics. The results of our study are encouraging and warrant further evaluation of the vault nanocapsule delivery platform for its full therapeutic potential in lung cancer and other malignancies.
Conceived and designed the experiments: SS LHR SMD VAK. Performed the experiments: UKK MKS FB AA SS MH. Analyzed the data: UKK MKS AA FB MH LHR SMD SS. Contributed reagents/materials/analysis tools: LHR SMD SS. Wrote the paper: UKK MKS LHR SMD SS.
- 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.
- 2. Kedersha NL, Rome LH (1986) Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103: 699–709.
- 3. Kong LB, Siva AC, Rome LH, Stewart PL (1999) Structure of the vault, a ubiquitous celular component. Structure 7: 371–379.
- 4. Kedersha NL, Heuser JE, Chugani DC, Rome LH (1991) Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol 112: 225–235.
- 5. Suprenant KA (2002) Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes? Biochemistry 41: 14447–14454.
- 6. Berger W, Steiner E, Grusch M, Elbling L, Micksche M (2009) Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 66: 43–61.
- 7. Champion CI, Kickhoefer VA, Liu G, Moniz RJ, Freed AS, et al. (2009) A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 4: e5409. Epub 2009 Apr 5430.
- 8. Stephen AG, Raval-Fernandes S, Huynh T, Torres M, Kickhoefer VA, et al. (2001) Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem 276: 23217–23220. Epub 22001 May 23210.
- 9. Kickhoefer VA, Garcia Y, Mikyas Y, Johansson E, Zhou JC, et al. (2005) Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc Natl Acad Sci U S A 102: 4348–4352. Epub 2005 Mar 4347.
- 10. Gunn M, Tangemann K, Tam C, Cyster J, Rosen S, et al. (1998) A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 695: 259–263.
- 11. Warnock RA, Campbell JJ, Dorf ME, Matsuzawa A, McEvoy LM, et al. (2000) The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med 191: 77–88.
- 12. Willimann K, Legler DF, Loetscher M, Roos RS, Delgado MB, et al. (1998) The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28: 2025–2034.
- 13. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, et al. (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164: 4558–4563.
- 14. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, et al. (2004) Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10: 2891–2901.
- 15. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, et al. (2006) Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 66: 3205–3213.
- 16. Kirk CJ, Hartigan-O'Connor D, Mule JJ (2001) The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61: 8794–8802.
- 17. Novak L, Igoucheva O, Cho S, Alexeev V (2007) Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 6: 1755–1764.
- 18. Liang CM, Zhong CP, Sun RX, Liu BB, Huang C, et al. (2007) Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 81: 9502–9511. Epub 2007 Jun 9513.
- 19. Wu S, Xing W, Peng J, Yuan X, Zhao X, et al. (2008) Tumor transfected with CCL21 enhanced reactivity and apoptosis resistance of human monocyte-derived dendritic cells. Immunobiology 213: 417–426. Epub 2007 Nov 2028.
- 20. Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP (2009) Regulated Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer. Cancer Microenviron 6: 6.
- 21. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, et al. (2008) Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non- Small Cell Lung Cancer. J Transl Med 6: 38.
- 22. Lai CY, Wiethoff CM, Kickhoefer VA, Rome LH, Nemerow GR (2009) Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer. ACS Nano 3: 691–699.
- 23. Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, et al. (2001) Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 92: 195–202.
- 24. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, et al. (1999) The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 146: 917–928.
- 25. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, et al. (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182: 6951–6958.
- 26. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, et al. (2009) Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106: 2729–2734. Epub 2009 Feb 2726.
- 27. Mikyas Y, Makabi M, Raval-Fernandes S, Harrington L, Kickhoefer VA, et al. (2004) Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP. J Mol Biol 344: 91–105.
- 28. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, et al. (2001) Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61: 6406–6412.
- 29. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, et al. (2003) SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2: 22.
- 30. Kickhoefer VA, Han M, Raval-Fernandes S, Poderycki MJ, Moniz RJ, et al. (2009) Targeting vault nanoparticles to specific cell surface receptors. ACS Nano 3: 27–36.
- 31. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, et al. (2000) Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27: 27–35.
- 32. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275–280.
- 33. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, et al. (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26: 4410–4417.
- 34. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168: 4272–4276.
- 35. Li L, Chao QG, Ping LZ, Xue C, Xia ZY, et al. (2009) The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm 24: 357–367.
- 36. Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455–458.
- 37. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–365.
- 38. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030–1037.
- 39. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, et al. (2006) CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582–1587.
- 40. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678–689.
- 41. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49–59.
- 42. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, et al. (2009) Population alterations of L: -arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14 (−)/CD15 (+)/CD33 (+) myeloid-derived suppressor cells and CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol.
- 43. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, et al. (2008) Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 57: 1493–1504.
- 44. Young MR, Newby M, Wepsic HT (1987) Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 47: 100–105.
- 45. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo MA, et al. (1989) Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J Cancer 44: 307–314.
- 46. Kusmartsev SA, Ogreba VI (1989) [Suppressor activity of bone marrow and spleen cells in C57Bl/6 mice during carcinogenesis induced by 7,12-dimethylbenz(a)anthracene]. Eksp Onkol 11: 23–26.
- 47. Kusmartsev SA, Li Y, Chen SH (2000) Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165: 779–785.
- 48. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636–645.
- 49. Kusmartsev SA, Kusmartseva IN, Afanasyev SG, Cherdyntseva NV (1998) Immunosuppressive cells in bone marrow of patients with stomach cancer. Adv Exp Med Biol 451: 189–194.
- 50. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, et al. (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336–4342.